Hubei Jianxiang Bioscience: difference between revisions
Diff·revision 4 → 5·19:09, 10 May 2025
Difference between revision 4 and revision 5 of Hubei Jianxiang Bioscience. 10 lines changed; the page grew by 1,955 bytes.
| Revision 4 — 16:32, 26 Apr 2025 SPPS_Sorrel (talk) add the reception tally with its period and count stated 2,874 bytes ±0 | Revision 5 — 19:09, 10 May 2025 UnderfillUna (talk) add the research-use-only statement to the lead rather than only the footer 4,829 bytes +1,955 | ||
|---|---|---|---|
| 10 | The organisation is one of twenty-eight covered on PeptidePedia under [[Project:Vendor notability]]. Like the others, it distributes material labelled [[Research use only|for research use only]], which is '''not approved for human use''' in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.{{r|ruo}} | 10 | The organisation is one of twenty-eight covered on PeptidePedia under [[Project:Vendor notability]]. Like the others, it distributes material labelled [[Research use only|for research use only]], which is '''not approved for human use''' in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.{{r|ruo}} |
| 11 | 11 | ||
| + | 12 | This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by [[Janoshik Analytical]], [[Medutest]], [[PeptideMeter]] and [[VendorInvestigate]].{{r|tally}} | |
| + | 13 | ||
| 12 | == Corporate identity and history == | 14 | == Corporate identity and history == |
| 13 | Incorporated in 2015 and based in Xianning, a prefecture-level city in southern Hubei rather than in the provincial capital, the organisation is among the smaller-city entities covered here.{{r|registry}} Hubei has a substantial fine-chemicals sector and Xianning sits within its industrial corridor; the organisation's registered scope is in bioscience, which corresponds to its trading activity.{{r|registry}} | 15 | Incorporated in 2015 and based in Xianning, a prefecture-level city in southern Hubei rather than in the provincial capital, the organisation is among the smaller-city entities covered here.{{r|registry}} Hubei has a substantial fine-chemicals sector and Xianning sits within its industrial corridor; the organisation's registered scope is in bioscience, which corresponds to its trading activity.{{r|registry}} |
| ⋮ | ⋮ | ||
| 15 | Purchaser reports note that shipments originate from a different city from the registered address. That is the ordinary arrangement in this sector — a registered address is a legal fact and a dispatch point is a logistical one — and the article records it because readers regularly ask which of the two the article's location field refers to. It refers to the registry record.{{r|registry,reports}} | 17 | Purchaser reports note that shipments originate from a different city from the registered address. That is the ordinary arrangement in this sector — a registered address is a legal fact and a dispatch point is a logistical one — and the article records it because readers regularly ask which of the two the article's location field refers to. It refers to the registry record.{{r|registry,reports}} |
| 16 | 18 | ||
| + | 19 | == Distribution and dispatch == | |
| + | 20 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. | |
| + | 21 | ||
| + | 22 | == Operations and documentation practice == | |
| + | 23 | Reports describe lyophilised material in crimped vials with a batch certificate, and packaging that has been consistent across submissions.{{r|reports}} Certificates in this set have generally reported purity, appearance and, on the incretin lines, a water figure.{{r|reports,usp1503}} | |
| + | 24 | ||
| 17 | == References == | 25 | == References == |
| 18 | {{reflist}} | 26 | {{reflist}} |
| ⋮ | ⋮ | ||
| 20 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> | 28 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> |
| 21 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 29 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| + | 30 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | |
| + | 31 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 22 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 32 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 23 | 33 |